#1* AURORA INVESTOR PRESENTATION APRIL 2019#2Disclaimer HORIZONTALLY DIVERSIFIED VERTICALLY INTEGRATED CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in contained in this presentation constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this presentation include, but are not limited to, statements with respect to accretive earnings, statements with respect to the funded production capacity which may not be achieved or realized within the time frames stated or at all, the anticipated size and or revenue associated with the adult consumer market in Canada and the global market for medical marijuana. Forward looking statements are based on certain assumptions regarding Aurora, including expected growth, results of operations, performance, industry trends and growth opportunities. While Aurora considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Recipients are cautioned not to place undue reliance on forward-looking statements contained herein. Forward-looking statements also necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the early stage of the cannabis industry in Canada generally, realization of funded production estimates, income tax and regulatory matters; the ability of Aurora to implement its business strategies; competition; currency and interest rate fluctuations; the risk of difficulties in the integration of Aurora and MedReleaf, the estimated size of the adult consumer market for cannabis in Canada, the estimated size of the global medical cannabis market and other risks. Recipients are cautioned that the foregoing risks are not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this presentation are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. Aurora disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Factors that could cause anticipated opportunities and actual results to differ materially include, but are not limited to, matters referred to above and elsewhere in Aurora's public filings and the material change reports that will be filed in respect of this Transaction, which are, or will be, available on SEDAR. AURORA 2#3Capturing Margin Throughout the Cannabis Value Chain Aurora is a leader in the domestic consumer market as well as the domestic and international medical cannabis markets. To achieve large-scale growth and long-term, sustainable profitability, Aurora has identified a number of elements critical to driving the success of its strategy. This dynamic growth strategy will enable Aurora to capture greater margin across the entire cannabis industry value chain. BRANDS Create unique brands and customer experiences that resonate both with the medical community and the adult consumer use market to help capture market share. DISTRIBUTION Develop strong domestic and international distribution partners and networks to ensure a broad market reach. SCIENCE Develop and acquire marketable intellectual property while strengthening our global medical brand and generating increased visibility. HORIZONTALLY SCALE Develop large scale, highly efficient production capacity in diverse geographic markets to serve the global demand for medical cannabis. DIVERSIFIED DIVERSIFICATION Develop a broad portfolio of high value-add products to deliver higher margins. INNOVATION Develop, adopt and acquire imovations across the entire camabis industry value chain to deliver efficiencies and create competitive advantages. COST OF PRODUCTION Adopt a purpose-built, high-technology, automated, yeid optimized facilty model that is replicable across the company's different markets ensuring consistently high-quality cannabis pro ducts produced at low costs. INTEGRATED VERTICALLY AURORA 3#4Aurora: leader in the global cannabis industry HORIZONTALLY DIVERSIFIED VERTICALLY E INTEGRATED Sector leader in technology across operations and product development Active in 5 continents and 24 countries Medical cannabis industry leader in Europe and Latin America 14 global production facilities() with 3 EU GMP certified (2) 15 strategic acquisitions across the value chain since August 2016 40 Clinical Studies underway or completed (3) and over 73,000 medical patients served 1. Excludes facilities from the recently closed ICC Labs acquisition. 2. Includes 2 production facilities in Canada and 1 European distribution center 3. Studies include randomized clinical trials and observational studies in addition to several case studies. AURORA 4#5Extensive Distribution Channels in Canada and Internationally HORIZONTALLY DIVERSIFIED Active in 24 countries across 5 continents MEXICO CANADA UNITED KINGDOM⚫ SPAIN DENMARK LITHUANIA LUXEMBOURG GERMANY CZECH REPUBLIC PORTUGAL ITALY ISRAEL MALTA CAYMAN ISLANDS COLOMBIA BRAZIL AUSTRALIA URUGUAY SOUTH AFRICA E INTEGRATED VERTICALLY AURORA 5#6Industry Leading Scale >500,000 kg/year funded capacity 11 Production facilities 150,000 120,000 current(¹) 500,000+(2) early 2019(3) mid 2020(3) Aurora defines production capacity as representing all planted rooms approved by Health Canada, factoring in anticipated harvests at maturity annualized for the following twelve (12) month period, based on an average historical yield per plant, as at February 15th 2019 2. Excludes recently closed acquisition of ICC Labs. 3. Based on calendar year. HORIZONTALLY DIVERSIFIED Production Capacity (kg/year) VERTICALLY INTEGRATED AURORA 6#7Cultivation Matters Mass Scale, High Quality and Low Cost Production is Crucial for Success Mass scale high-tech facilities designed to meet the fast- growing global demand for cannabis in the medical and adult usage markets Focus on high quality products, allows Aurora to service various end markets, starting with medical and pharma", through precise control of cultivation variables (nutrients, lighting, humidity, temperature, air flow, etc.) Low cost production enables Aurora to execute on its high-margin strategy 1. Medical cannabis requires consistent and high-quality product. HORIZONTALLY DIVERSIFIED VERTICALLY INTEGRATED AURORA 7#8Strong Revenue, Patient and Production Growth $60 277% CAGR $50 $40 $30 Quarterly Revenue (C$ mm) $20 $10 $0 90 HORIZONTALLY DIVERSIFIED INTEGRATED VERTICALLY Registered Medical Patients Grams Produced Registered Medical Patients 9,000,000 80,000 8,000,000 70,000 7,000,000 60,000 6,000,000 5,000,000 50,000 40,000 4,000,000 3,000,000 2,000,000 1,000,000 30,000 20,000 10,000 Grams of Dried Flower Equivalents Dec-18 Sep-18 Jun-18 Mar-18 Dec-17 Sep-17 Jun-17 Mar-17 Dec-16 Sep-16 Jun-16 Mar-16 Dec-15 Sep-15 Jun-15 Mar-15 Dec-14 Dec-18 Sep-18 Jun-18 Mar-18 Dec-17 Sep-17 Jun-17 Mar-17 Dec-16 Sep-16 AURORA 8#9Significant Opportunity Across Medical, Consumer and Wellness Markets Expected global disruption in the beverage, pharmaceutical, CPG and tobacco industries Source. BMO Research and Deloitte 1. Estimated for Canadian Medical TAM assumes LPs obtain retail prices for cannabis. 2. Estimate for total potential market opportunity for Canadian Adult-Use. ~$115+ billion -$70+ Global Consumer(4) billion ~$3 billion Canadian Medical(¹) ~$9 billion Canadian Consumer(2) Global Medical (3) Total global cannabis opportunity is ~$200 billion HORIZONTALLY DIVERSIFIED INTEGRATED VERTICALLY 3. Estimate consists of medical markets for the US, EU and LATAM markets only and assumes EU and LATAM TAM based on wholesale pricing while US TAM assumes retail pricing. 4. Estimate consists of adult-use markets for the US. and EU markets only and assumes that LPs obtain retail pricing for cannabis. AURORA 9#10Significant Canadian Opportunities Across Medical, Consumer, and Wellness Markets Medical Consumer HORIZONTALLY DIVERSIFIED VERTICALLY INTEGRATED Product Mix dry flower oils soft gels gel caps vape pens edibles infused beverages Margin (Outlook) Improving as contribution from derivatives increases Keys to Success Enhanced Margin through Premium and Innovative Products Patient capture Drive down costs Product innovation Branding through clinical trials R&D to develop high margin products Comprehensive house of brands Leverage medical reputation and credibility AURORA 10#11Successful Canadian Consumer Market Launch 17 awards lift CANADIAN CANNABIS AWARDS 2017 Top 4 of 5 Best-Selling Products in B.C(¹) from the Canadian Cannabis Awards TANGERINE DREAM San Rafael'71 MedReleaf GREAT WHITE SHARK San Rafael'71 MedReleaf BLUE DREAM Aurora by Aurora Cannabis Comprehensive portfolio of medical and consumer brands: MedReleaf. CanniMedⓇ Therapeutics Inc. * AURORA ALTAVIE EV I O BIDIOL PLANETHEMP 1. Sourced from BC Cannabis Stores website; data taken as of February 19th 2019 and represents the first two weeks of legal sales. HORIZONTALLY DIVERSIFIED PINK KUSH San Rafael'71 MedReleaf E INTEGRATED VERTICALLY San Rafael WOODSTOCK AURORA 11#12Significant Global Opportunities Across Medical, Consumer, and Wellness Markets Medical Product Mix dry flower oils Consumer HORIZONTALLY DIVERSIFIED VERTICALLY INTEGRATED infused beverages nutraceuticals wellness recovery products beverages Margin (Outlook) Clinical Trials and New Treatment Uses Drive Higher Margins Keys to Success Leveraging early mover advantage Higher-margin, pharma-grade product innovation Strong medical brand and market awareness Innovative Product Formats and Brands to Extend Margins Controlling distribution First-mover into new countries to establish leading market share Addressing the non-prescription wellness market AURORA 12#13Poised to Capture the Global Hemp-CBD Opportunity HORIZONTALLY DIVERSIFIED VERTICALLY INTEGRATED The global Hemp-CBD market is estimated to reach ~US$22bn + by 2022 (1) Growing Use Cases for CBD Products . Hemp-CBD is increasingly being used in a variety of products for a number of health & wellness purposes including: nutrition, inflammation reduction, boosting metabolism, lowering anxiety and improving overall mood HEMPCO agropro BORELA a leading processor & marketer of help based products and brands Europe's largest producer, processor and supplier of organic hemp and hemp products a European hemp processor and distributor a global trailblazer in high-tech CBD extraction at scale RADIENT ICCLABS Source: Brightfield Group. 1. Note estimate includes markets where medical and /or recreational use of cannabis is not currently legally permitted, such as the U.S. a South American pioneer in cannabis and hemp-based products AURORA 13#14A Global Rational Market Builder Leadership Across the Entire Value Chain HORIZONTALLY DIVERSIFIED 1 2 BUILDING CULTIVATION & EXTRACTION 3 PLANT | MEDICAL SCIENCE & PRODUCT R&D 4 5 DISTRIBUTION CONSUMER ENGAGEMENT & BRANDS Over 30 years of experience in designing and engineering high-tech, automated, environmentally controlled greenhouses Disruptive extraction technology to ensure low-cost, high yield operations Industry leading genetics research and robust product innovation, driven by the industries largest science team Robust domestic and international distribution networks spanning 98% of the Canadian population and other locations worldwide Well-recognized and respected medical and consumer brands with strong consumer engagement and customer care INTEGRATED VERTICALLY AURORA 14#15Strategically Investing Across the Value Chain DEC 2016 RADIENT Aurora is exceptionally well positioned, through its diverse acquisitions and strategic initiatives completed to date, to capitalize on the enormous opportunity across the entire cannabis industry value chain in both domestic and international markets. Acquisitions DEC 2017 DEC 2017 AUG 2018 SEP 2018 SEP 2018 MAR 2017 MAR 2018 Larssen Ltd BORELA BIOPHARMA Cricutings Peloton agropro CanniMed Thempou lac JULY 2018 JUNE 2018 OCT 2017 OCT 2017 AUG 2016 MAY 2017 MED DELOMBIA ANANDIALABS Urban Cultivator canvas PEDANIOS JUNE 2017 HEMPCO SEP 2017 Flora fotonica Strategic Investments JULY 2018 MedReleaf NOV 2018 ICCLABS MAR 2019 Whistler CANNABIS.CO. HORIZONTALLY DIVERSIFIED JAN 2018 MAY 2018 JUNE 2018 FEB 2018 MAR 2017 JUNE 2018 JULY 2018 DEC 2018 micronwaste CIPharma CAPCIUM ALCANNA CANN GROUP LIMITED Chan EV 10 HIGHTIDE INTEGRATED VERTICALLY AURORA 15#16Diverse Domestic Medical Distribution Networks Medical Market Aurora has agreements to collaborate with PharmaChoice, Pharmasave and Shoppers Drug Mart on the marketing, distribution, and sale of medical cannabis products through their respective networks of pharmacies, subject to Health Canada approval. Consumer Market Aurora's distribution network covers approximately 98 per cent of the Canadian population. The Aurora and Med Releaf brands, including San Rafael '71 and AltaVie, have rapidly achieved a strong presence across the country, positioning Aurora well for rapid growth. HORIZONTALLY DIVERSIFIED SHOPPERS DRUG MART PHARMASAVEⓇ PharmaChoice VERTICALLY INTEGRATED AURORA 16#17Establishing EU Market Leadership European Union Population: ~465 million | Market Opportunity: ~C$98 billion HORIZONTALLY DIVERSIFIED VERTICALLY INTEGRATED GERMANY - The acquisition of Pedanios, now Aurora Deutschland, provides distinct first mover advantage in the single largest federally legalized medical cannabis market with a population of 82+ million in Germany EU GMP certified facilities necessary for success in the EU markets Aurora currently holds a leading market share in the German medical market 70+ employees across Germany and the EU Germany has broad insurance coverage for medical cannabis, allowing for substantially higher margins and is expected to reduce margin compression over time Uniquely positioned to capture a significant market share as the German industry matures DENMARK - First LP to ship medical cannabis to Denmark. Aurora also has Aurora Nordic, a 51% owned, 1,000,000 sq ft facility is being built in Odensk, along with a 100,000 sq ft retrofit facility MALTA - First LP to receive cultivation LOI issued by the Maltese authorities to date and first LP to ship medical cannabis to Malta UNITED KINGDOM - Authorities recently granted Aurora approval for its first shipment of medical cannabis into the UK from Canada - ITALY Supplying cannabis to the Italian government through Aurora Europe. First LP to complete private export from Canada in April 2018 CZECH REPUBLIC - Supplying cannabis to Czech Medical Herbs s.r.o. ("CMH"), a Czech pharmaceutical wholesaler, for distribution to pharmacies throughout the country LUXEMBOURG - Selected by the Luxembourg Health Ministry for the supply of medical cannabis through an initial purchase order for approximately 20 kilograms POLAND - First LP to receive cannabis import permit from the Polish Ministry of Health Source: BMO Research. 1. Estimated to be completed by calendar H2 2019 AURORA 17#18HORIZONTALLY DIVERSIFIED Leadership in Latin America Population: ~650 million ICC Labs Estimated funded production capacity over 450,000 kg per annum of bulk hemp and cannabis Two facilities currently under development adding 124,000 sq ft of greenhouse production in Colombia and a 1,000,000 sq ft facility in Uruguay Outdoor grow sites, with a potential total area of over 800 acres Broad portfolio of dried flower and higher margin products, including tablets, softcaps, ointments, creams, drops infused syrups, and patches South America's first GMP compliant, cannabis science laboratory, to be scaled up to 150,000 kg extraction capacity pp year COLUMBIA URUGUAY Significant Latin American Market Opportunity with Clear Demand for Legal Regulated Cannabis Products Uruguay was the first country in the world to fully legalize medical and adult use cannabis, allowing cultivation of CBD rich bulk hemp with THC concentrations of up to 1% INTEGRATED VERTICALLY Colombia legalized medical cannabis in 2015 and MED Colombia received its cultivation license for THC cannabis and its derivatives in 2017 Through the acquisition of Farmacias Magistrales, Aurora will become Mexico's first and only federally licensed importer of medical cannabis containing over 1% THC AURORA 18#19Q2 2019 Results $ in Canadian millions, unless otherwise noted HORIZONTALLY DIVERSIFIED Q2 2019 Q1 2019 Change (%) Q2 2018 Change (%) VERTICALLY INTEGRATED Financial Net Revenue $54.2 $29.7 83% $11.7 363% Gross Margin on Net Cannabis Revenue(¹) 54% 70% (23%) 63% (15%) Biological Inventory $89.1 $80.8 10% $17.3 418% Cash Cost to Produce (per gram of dried cannabis sold) (2) $1.92 $1.45 33% $1.41 22% Operational Average Net Selling Price of Dried Cannabis Average Net Selling Price of Cannabis Extracts $6.23 $8.39 (26%) $7.86 (21%) $10.00 $12.12 (18%) $13.35 (25%) Kilograms Produced 7,822 4,996 57% 1,204 550% Kilograms Sold 6,999 2,676 162% 1,162 502% 1. Represents the gross margin on net cannabis revenue before fair value adjustments. Excludes revenues from patient counselling services, design, engineering, and construction services, and analytical testing services. Gross margin on net cannabis revenue is a non- IFRS financial measure. See "Gross Margin" section of Q2 2019 MD&A for reconciliation to IFRS figure. 2. Represents the cash cost of sales per gram of dried cannabis produced and sold by consolidated Aurora, excluding costs to sell such as packaging costs. Cash cost of sales per gram produced is a non-IFRS financial measure. See "Cash Cost of Sales of Dried Cannabis and Cash Cost to Produce Dried Cannabis Sold - Aurora Produced Cannabis" section of Q2 2019 MD&A for reconciliation to IFRS figure. AURORA 19#20Aurora's Path to Profitability NEAR TERM Drive down costs by leveraging massive scale • Protecting against eventual margin compression Leadership in Global Medical Markets Invest heavily in R&D to create optionality Brand building and protection through high-quality product HORIZONTALLY DIVERSIFIED MEDIUM TERM Harvest Canadian market cash flow from near term domestic strategy Leverage R&D work in higher margin products (Vapes, CBD infusions, etc.) Global Medical leading to higher margin sales VERTICALLY INTEGRATED LONG TERM Branded high margin products across both global medical and consumer markets 0 R&D supports product development, brand development, and continued improvement in yields AURORA 20#21HORIZONTALLY DIVERSIFIED VERTICALLY INTEGRATED High Margin Strategy A Sustainable Long-term Business Model Maximizing average selling price through. Leadership in key international markets allowing strategic focus on highest margin options (medical, new products) Full margin capture in international markets through direct ownership of distribution channels Commitment to science and product development > developing new higher margin products and marketable IP Driving down overall production per gram cash costs through. Commitment to science and technology > increasing yields through genetics, low per gram operating costs from world-class automation and replicable large-scale pharma-style production Low input-cost locations Leveraging massive scale to spread costs over a large volume of product Production costs at scale are projected to be well below $1 per gram AURORA 21#22HORIZONTALLY DIVERSIFIED Scientific Leadership Advantage Industry Leading Science & Innovation Team to Drive Medical Advancements Jon Page, PhD Chief Science Officer First scientist to sequence the cannabis genome and provide deep insights into the biosynthesis of cannabinoids Jason Dyck, PhD Human Scientist, Director Professor in the Department of Pediatrics at the University of Alberta and a Canada Research Chair in Molecular Medicine 40 Clinical Studies Underway or Completed"> 7 Pre-Clinical Studies in Progress 27 Clinical Studies Currently Under Discussion VERTICALLY INTEGRATED Kelly Narine, PhD Head of Biomedical Research PhD in Medical Genetics from the University of Alberta; Deep expertise in translating research into positive health outcomes Shane Morris, PhD Head of Product Development Experienced executive in the cannabis industry since 2015; previously part of the senior leadership team at Hydropothecary With Strong IP Retention on Clinical Studies Clinical Research Areas include. Pain, Epilepsy, PTSD, Anxiety. Opioid Sparing, Cancer, Neurodegeneration Canada MRC CMRC UNIVERSITY OF TORONTO McGill UNIVERSITY Partnering with Leading Institutions and Universities UNIVERSITY IVERSITY OF OF MANITOBA UBC THE UNIVERSITY OF BRITISH COLUMBIA 1. Studies include randomized clinical trials and observational studies in addition to several case studies.. UNIVERSITY OF SASKATCHEWAN Mount Sinai Hospital Sinai Health System Joseph & Wolf Lebovic Health Complex camh Centre for Addiction and Mental Health ser mental Mater Ce AURORA 22#23Proven Management Team Driving High Pace of Execution HORIZONTALLY DIVERSIFIED INTEGRATED VERTICALLY Terry Booth Chief Executive Officer CEO of 6 successful companies with 25 years experience in highly regulated industries Steve Dobler President Successful entrepreneur, member of many public companies' board of directors. Responsible for raising substantial funds for Aurora Glen Ibbott Chief Financial Officer Strong senior financial executive with extensive life sciences sector experience Cam Battley Chief Corporate Officer Deep experience in pharma and cannabis sectors, Board member Cannabis Canada Neil Belot Chief Global Business Development Officer Former executive director of Cannabis Canada - Canada's trade association for Licensed Producers Jillian Swainson Chief Legal Officer Former Partner at Brownlee LLP with experience in corporate, commercial, intellectual property and securities law and providing advisory services in highly regulated industries Darren Karasiuk Chief Commercial Officer Successfully launched Aurora into the Canadian consumer market, achieving strong brand recognition for Aurora's brands. Former VP Insights & Advisory at Deloitte Debra Wilson Chief Human Resources Officer Seasoned leader with more than 25 years' experience in human resources. developing and practicing leading edge methods Darryl Vleeming Chief Information Officer Over 20 years of experience in Senior IT leadership. project delivery, and IT strategic planning at publicly traded international corporations. Jonathan Page Chief Science Officer Globally renowned cannabis scientist. Co-lead of the Canadian team of scientists who first sequenced the cannabis genome. Co-Founder of Anandia Labs Allan Cleiren Chief Operating Officer Experienced operational executive with nearly three decades leadership experience at private and public companies AURORA 23#24Strong Board of Directors HORIZONTALLY DIVERSIFIED Michael Singer Executive Chairman Former CFO, Clementia Pharmaceuticals Former CFO, Bedrocan Canada Corp. Terry Booth Chief Executive Officer CEO of 6 successful companies 25 years experience in highly regulated industries Steve Dobler President Successful entrepreneur, member of many public companies' board of directors. Responsible for raising substantial funds for Aurora Shan Atkins Director Certified Public Accountant with over 20 years of corporate leadership experience. Served on public company boards, including Shoppers Drug Mart Dr. Jason Dyck Director Professor in the Department of Pediatrics and Director of Cardiovascular Research Centre, University of Alberta Norma Beauchamp Director Retired President and CEO of Cystic Fibrosis Canada, Director of Acerus Pharmaceuticals Ronald Funk Director Deep consulting business experience, former VP Corporate Affairs and Competitive Improvement for Rothmans Adam Szweras Director Experienced securities lawyer, Founder of US developer of marijuana, hemp oil, and edible products Deep Expertise and Background in Cannabis, Hemp, Tobacco and Pharmaceutical INTEGRATED VERTICALLY AURORA 24#25Checking All the Boxes - A Platform for Accelerated Growth Industry Leading Scale Enhanced Diversification HORIZONTALLY DIVERSIFIED INTEGRATED VERTICALLY $ Low Production Costs and Industry Leading Yields Extensive Distribution Channels in Canada and Internationally Proficient M&A Capabilities Proven Execution & Agility Across Value Chain Award Winning Product Lines Support Brand Leadership Innovation and R&D Excellence h Business Integration Enhanced Capital Markets Expertise Profile AURORA 25#26Cam Battley Chief Corporate Officer [email protected] AURORA CONTACT INFORMATION Marc Lakmaaker VP Investor Relations [email protected] Investor Relations 1-855-279-4652 [email protected]#27AURORA APPENDIX#28SIZE CAPACITY STATUS Industry Leading Scale 14 Production Facilities - Expected to Have Over 500,000 kg/year in Capacity by Mid-2020 LOCATION HORIZONTALLY DIVERSIFIED VERTICALLY INTEGRATED LICENSE CULTIVATION SALE Aurora Mountain Mountain View, Alberta, Canada 55,200 sq.ft. 4,800 kg/year Operating since 2015 Aurora Vie Pointe Claire, Quebec, Canada 40,000 sq.ft. 4,000 kg/year Operating since June 2018 CANADA Aurora Eau Aurora Sky Aurora Sun Lachute, Quebec, Canada 48,000 sq.ft. 4,500 kg/year Facility in full operation Edmonton, Alberta, Canada 800,000 sq.ft. >100,000 kg/year Facility in full operation Medicine Hat, Alberta, Canada 1,200,000 sq.ft. >150,000 kg/year WHISTLER ALPHA LAKE AURORA SKY. WHISTLER PEMBERTON AURORA MOUNTAIN CANNIMED AURORA SUN Aurora Nordic 1 Odense, Denmark 100,000 sq.ft. 8,000 kg/year Aurora Nordic 2 Odense, Denmark 1,000,000 sq.ft. >120,000 kg/year CanniMed Saskatoon, Saskatchewan, Canada 97,000 sq.ft. 19,000 kg/year Full construction to be completed by mid calendar 2020 Facility construction complete Full construction to be complete by mid calendar 2020 Operating since 2004. Facility upgrades underway AURORA EAU AURORA VIE SOUTH AMERICA BRADFORD EXETER MARKHAM Markham Markham, Ontario, Canada 55,000 sq.ft. 7,000 kg/year Operating since 2014 Bradford Bradford, Ontario, Canada 210,000 sq.ft. 28,000 kg/year Facility in full operation DENMARK Exeter Exeter, Ontario, Canada 1,000,000 sq.ft. 105,000 kg/year Land and building purchased Whistler Alpha Lake Whistler, British Columbia, Canada 12,500 sq. ft. 500 kg/year Whistler Pemberton Pemberton, British Columbia, Canada 62,000 sq. ft. >5,000 kg/year Operating since 2014 Phase 1 in operation. Phase 2 expected to be completed in September 2019 ICC LABS AURORA NORDIC ICC Labs Canelones, Uruguay 21,000 sq.ft. 27,135 kg/year Facility in full operation. AURORA 28#29Executing on the Global Cannabis Opportunity HORIZONTALLY DIVERSIFIED VERTICALLY INTEGRATED Distribution ALCANNA Extraction RADIENT Cultivation THE GREEN ORGANIC • Largest Canadian private retailer of adult beverages including beer, wine, spirits Bringing a state-of-the-art consumer retail concept featuring a variety of brands and wide selection of cannabis products Opening 37 stores and retrofitting existing liquor stores into cannabis retail outlets Investment aids rapid development of Canadian cannabis retail network •-17% ownership interest • Proprietary technology provides superior ingredient purity, yield, and cost Aligned with strategy of becoming the leading vertically integrated player considering the growing importance of cannabis extracts Existing investment accomplished objective of securing supply agreement for 20% of TGOD's organic cannabis production Plant Science and Product R&D HEMPCO Flora Fotonica micronwaste TECNOLOGIES CIPharma CAPCIUM Inc. • Leading processor & marketer of hemp based products and brands Developer of advanced grow light technologies Leading organic waste technology company that developed an on-site system that turns organic waste into clean water Provides safe, flexible, simple and innovative drug delivery systems for pain management therapies and treatments Platform specializing in softgel encapsulation; expands Aurora's differentiated, higher- margin product offerings Consumer Engagement and Brands Спост EV 10 WAGNERWD DIMASING Curated cannabis retailer with access to "craft" cannabis supply, and diverse brands for consumers Comprised of a portfolio of conscious lifestyle brands Technology enables the production of over 75 different pre-rolled product types. addressing a wide variety of market demands Developing a network of cannabis and accessory retail stores, as well as manufacturing and distributing branded cannabis accessories 2012 First mover in Australia focused on developing medicinal DUTCHMAN CANN GROUP LIMITED cannabis products HIGHTIDE AURORA 29#30Select Portfolio of Clinical Studies Indication Research Partners Trial Name Cancer Pain Management OCOG, Sunnybrook Health Science Center, Hamilton Health Sciences, Juravinski Cancer Center Cannabis Oil for Pain Effectiveness Osteoarthritis Epilepsy Tourette's Syndrome Pharmacokinetics McGill University Health Network & Queen Elizabeth II Health Science Center Royal University Hospital and University of Saskatchewan University Health Network N.A. Vaporized Cannabis for Painful Osteoarthritis of the Knee CBD in Children with Refractory Epilepsy Vaporized Cannabis in Adults with Tourette's Syndrome Comparative Bioavailability and Pharmacogenomics Study of THC on Healthy Volunteers Epilepsy Ontario Brain Institute, UofT, University Health Network, University Hospital London, Toronto Western Hospital CBD and THC Given as Adjunctive Therapy to Adults with Refractory Seizures HORIZONTALLY DIVERSIFIED Phase = lla ' || = III Genetics Mount Sinai Hospital Identification of Genetic Biomarker Signatures associated with Cannabis Efficacy and Dose in Survey Patients N.A. Chronic Pain CFL Alumni Association, CannaConnect Clinic Assessing the Effects of Medical Cannabis on Pain and Related Quality of Life in Retired Athletes with Chronic Pain N.A. Multiple Medical Conditions University of Alberta Health and Economics-Based Outcomes of Cannabis-Based Therapies N.A. INTEGRATED VERTICALLY AURORA 30